FIELD: medicine.
SUBSTANCE: invention relates to the use of 21-hemisuccinate hydrocortisone (RX624) as Alzheimer's disease treatment, as well as to the use of 21-hemisuccinate hydrocortisone in the production of drugs for the treatment of Alzheimer's disease.
EFFECT: use of RX624 in transgenic mice with genetically determined Alzheimer's disease leads to selective inhibition of the formation of the exogenous GAFD-A complex and stops memory impairment in animals according to the results in the Morris water test.
2 cl, 3 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| 4-(3-((2-ADAMANTYL)AMINO)-3-OXOPROP-1-EN-1-YL)-N-HYDROXYBENZAMIDE - A NEW DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | 2022 |
|
RU2783995C1 |
| REDUCED SYSTEMIC LEVEL OF REGULATORY T-CELLS OR THEIR ACTIVITY FOR TREATING CNS DISEASES AND TRAUMAS | 2016 |
|
RU2741366C2 |
| REDUCED SYSTEMIC LEVELS OR ACTIVITY OF REGULATORY T-CELLS FOR TREATING DISEASE AND CENTRAL NERVOUS SYSTEM INVOLVEMENT | 2017 |
|
RU2815892C1 |
| REDUCED LEVELS OR ACTIVITY OF SYSTEMIC REGULATORY T CELLS FOR TREATING DISEASE OR CNS INJURY | 2015 |
|
RU2690670C2 |
| PEPTIDE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE | 2018 |
|
RU2679080C1 |
| METHOD FOR TREATING NEURODEGENERATIVE DISEASES | 2021 |
|
RU2777871C1 |
| PEPTIDE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE | 2018 |
|
RU2679059C1 |
| USE OF A BENZOPYRAN DERIVATIVE FOR THE TREATMENT OF DEMENTIA OF ALZHEIMER'S TYPE ASSOCIATED WITH CALCIUM DYSREGULATION | 2023 |
|
RU2804398C1 |
| TARGETED NON-INVASIVE TRANSPLANTATION INTO BRAIN OF FUNCTIONALLY ACTIVE MITOCHONDRIA FOR TREATING NEURODEGENERATIVE DISEASES | 2019 |
|
RU2744453C2 |
| PHARMACEUTICAL COMPOSITION BASED ON HAEE PEPTIDE FOR TREATING NEURODEGENERATIVE DISEASES | 2019 |
|
RU2709539C1 |
